Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free ONT Stock Alerts

Oxford Nanopore Technologies (ONT) Competitors

Oxford Nanopore Technologies logo
GBX 170 +5.50 (+3.34%)
As of 08/21/2026 12:13 PM Eastern
Compare

ONT vs. ABC, OXB, SLN, AVCT, and HZD

Should you buy Oxford Nanopore Technologies stock or one of its competitors? Oxford Nanopore Technologies's main competitors and comparable companies include Abcam (ABC), Oxford Biomedica (OXB), Silence Therapeutics (SLN), Avacta Group (AVCT), and Horizon Discovery Group plc (HZD.L) (HZD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Oxford Nanopore Technologies (LON:ONT) and Abcam (LON:ABC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

18.3% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oxford Nanopore Technologies had 13 more articles in the media than Abcam. MarketBeat recorded 13 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Abcam's average media sentiment score of 0.00 beat Oxford Nanopore Technologies' score of -0.12 indicating that Abcam is being referred to more favorably in the news media.

Company Overall Sentiment
Oxford Nanopore Technologies Neutral
Abcam Neutral

Oxford Nanopore Technologies presently has a consensus target price of GBX 193.25, suggesting a potential upside of 13.68%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Abcam
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M7.06-£175.21M-£15.10N/A
Abcam£350.40M0.00N/A£0.06N/A

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-54.66% -35.45% -14.42%
Abcam N/A N/A N/A

Summary

Abcam beats Oxford Nanopore Technologies on 7 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-54.66% -35.45% -14.42%
Oxford Biomedica -17.85%-48.56%-12.67%

Oxford Nanopore Technologies presently has a consensus target price of GBX 193.25, indicating a potential upside of 13.68%. Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 11.13%. Given Oxford Nanopore Technologies' higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Oxford Nanopore Technologies had 10 more articles in the media than Oxford Biomedica. MarketBeat recorded 13 mentions for Oxford Nanopore Technologies and 3 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of -0.12 beat Oxford Biomedica's score of -0.44 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Nanopore Technologies
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford Biomedica
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

18.3% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oxford Nanopore Technologies has a beta of 0.912, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M7.06-£175.21M-£15.10N/A
Oxford Biomedica£168.74M3.75-£143.51M-£26.92N/A

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 8 of the 14 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

18.3% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oxford Nanopore Technologies has a consensus target price of GBX 193.25, suggesting a potential upside of 13.68%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Oxford Nanopore Technologies -54.66%-35.45%-14.42%

In the previous week, Oxford Nanopore Technologies had 13 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat Oxford Nanopore Technologies' score of -0.12 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Silence Therapeutics Neutral
Oxford Nanopore Technologies Neutral

Silence Therapeutics has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Oxford Nanopore Technologies£235M7.06-£175.21M-£15.10N/A

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Nanopore Technologies (LON:ONT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Oxford Nanopore Technologies had 12 more articles in the media than Avacta Group. MarketBeat recorded 13 mentions for Oxford Nanopore Technologies and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.67 beat Oxford Nanopore Technologies' score of -0.12 indicating that Avacta Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avacta Group
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford Nanopore Technologies
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Avacta Group has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K2,778.12-£30.08M-£9.66N/A
Oxford Nanopore Technologies£235M7.06-£175.21M-£15.10N/A

Avacta Group currently has a consensus price target of GBX 99, suggesting a potential upside of 47.76%. Oxford Nanopore Technologies has a consensus price target of GBX 193.25, suggesting a potential upside of 13.68%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Oxford Nanopore Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.912, suggesting that its stock price is 9% less volatile than the broader market.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 18.3% of Oxford Nanopore Technologies shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies has a net margin of -54.66% compared to Avacta Group's net margin of -33,961.06%. Oxford Nanopore Technologies' return on equity of -35.45% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-33,961.06% -2,929.47% -21.80%
Oxford Nanopore Technologies -54.66%-35.45%-14.42%

Summary

Avacta Group beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Horizon Discovery Group plc (HZD.L)?

Oxford Nanopore Technologies (LON:ONT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -54.66%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-54.66% -35.45% -14.42%
Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Horizon Discovery Group plc (HZD.L) has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M7.06-£175.21M-£15.10N/A
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A

18.3% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies had 13 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 13 mentions for Oxford Nanopore Technologies and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 beat Oxford Nanopore Technologies' score of -0.12 indicating that Horizon Discovery Group plc (HZD.L) is being referred to more favorably in the news media.

Company Overall Sentiment
Oxford Nanopore Technologies Neutral
Horizon Discovery Group plc (HZD.L) Neutral

Oxford Nanopore Technologies currently has a consensus target price of GBX 193.25, suggesting a potential upside of 13.68%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Horizon Discovery Group plc (HZD.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Horizon Discovery Group plc (HZD.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Oxford Nanopore Technologies beats Horizon Discovery Group plc (HZD.L) on 8 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONT vs. The Competition

Export
MetricOxford Nanopore TechnologiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£1.66B£4.01B£7.37B£2.54B
Dividend YieldN/A3.64%2.53%6.17%
P/E Ratio-11.2611.62272.60367.57
Price / Sales7.061,334.62623.8383,481.74
Price / Cash4.04105.1478.6227.89
Price / Book2.5316.8013.057.19
Net Income-£175.21M-£12.50M£3.47B£5.89B
7 Day Performance36.68%3.29%2.09%0.30%
1 Month Performance57.85%8.23%6.64%3.31%
1 Year Performance-18.35%55.05%25.02%22.13%

Oxford Nanopore Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONT
Oxford Nanopore Technologies
1.925 of 5 stars		GBX 170
+3.3%		GBX 193.25
+13.7%		-18.3%£1.66B£235MN/A1,281
ABC
Abcam
N/AN/AN/AN/A£2.81B£350.40M20,433.331,650
OXB
Oxford Biomedica
1.5284 of 5 stars		GBX 493.05
+0.2%		GBX 580.85
+17.8%		-2.5%£596.78M£168.74MN/A891
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35MN/A100
AVCT
Avacta Group
2.4394 of 5 stars		GBX 65.11
-0.6%		GBX 99
+52.0%		+38.0%£305.08M£113KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel